BCL2L2 and hepatocellular carcinoma: Our findings indicate that the MT1JP/miR-24-3p/BCL2L2 axis contributes to resistance of HCC cells to Lenvatinib and that targeting MT1JP-induced apoptosis may be a promising strategy to overcome TKI resistance in human HCC.